ReviewFrontiers in cellular and infection microbiology2022
Research Progress on the Correlation Between
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Occurrence and relevance of Gardnerella vaginalis in urine cultures of kidney transplant recipients- a retrospective cohort analysis.BMC microbiology · 2026Article
- The Relationship of Vaginal Symptoms and Cervical Inflammation Severity with Cytological Abnormalities and HPV Positivity: A Prospective Observational Study.Biomedicines · 2026Article
- Association BetweenMicroorganisms · 2026Article
- Glycan Profile Alterations in Vaginitis and Their Role in Pathogen-Host Interactions.Polish journal of microbiology · 2025Review
- Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.NPJ biofilms and microbiomes · 2025Review
- Age-related vaginal microecology and infection epidemiology among premenopausal and postmenopausal gynecologic outpatients: a cross-sectional study.Frontiers in cellular and infection microbiology · 2025Article
- Computational approach for drug discovery against Gardnerella vaginalis in quest for safer and effective treatments for bacterial vaginosis.Scientific reports · 2024Article
- IgA coating of vaginal bacteria is reduced in the setting of bacterial vaginosis (BV) and preferentially targets BV-associated species.Infection and immunity · 2024Article
- The role of sialidases in the pathogenesis of bacterial vaginosis and their use as a promising pharmacological target in bacterial vaginosis.Frontiers in cellular and infection microbiology · 2024Review
- Under conditions closely mimicking vaginal fluid,Microbiology (Reading, England) · 2023Article
- Biofilm-Forming Capacity and Drug Resistance of DifferentMicroorganisms · 2023Article
- Distinct mucosal and systemic immunological characteristics in transgender women potentially relating to HIV acquisition.JCI insight · 2023Article
- Metabolic Network Models of themSystems · 2023Article
- Effect of a combination of pea protein, grape seed extract and lactic acid in an in vivo model of bacterial vaginosis.Scientific reports · 2023Article
- VaginalFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial vaginosis (BV) is the most common infectious disease of the reproductive tract in women of childbearing age. It often manifests as an imbalance in the vaginal microbiome, including a decrease in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.